# Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy

> **NCT06687876** · PHASE2 · RECRUITING · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 14 (estimated)

## Conditions studied

- Oesophageal Adenocarcinoma
- Tumor Microenvironment

## Interventions

- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT06687876
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-09
- **Primary completion:** 2026-12
- **Final completion:** 2030-12
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2025-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06687876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06687876, "Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT06687876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*